Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
38I Stock Chart & Stats
€11.48
-€0.50(-4.02%)
At close: 4:00 PM EST
€11.48
-€0.50(-4.02%)
Day’s Range― - ―
52-Week Range€5.30 - €24.34
Previous CloseN/A
Volume0.00
Average Volume (3M)427.00
Market Cap
€1.34B
Enterprise Value€1.53B
Total Cash (Recent Filing)€449.88M
Total Debt (Recent Filing)€93.33M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Apr 30, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding118,133,545
10 Day Avg. Volume582
30 Day Avg. Volume427
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.12Price Target Upside57.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)-3.14
Revenue Forecast (FY)€50.51M
Bulls Say, Bears Say
Bulls Say
Clinical DataClinical data showing stabilization in walking distance and robust suppression of a disease biomarker suggest potential functional benefit even in patients with advanced symptoms.
Commercial InterestStrong physician interest and higher-than-expected enrollment in the HAE program for lonvo-z, with no severe liver safety signal, support promising commercial potential for related gene‑editing approaches.
RegulatoryFDA removal of the clinical hold on the MAGNITUDE trial allows enrollment to restart under agreed safety measures and reduces regulatory uncertainty around the ATTR development program.
Bears Say
Enrollment And EligibilityEnhanced hepatic monitoring, short‑term steroid guidance, and stricter exclusion criteria could meaningfully reduce the addressable patient pool and slow trial enrollment.
Payer ResistancePotential payer resistance to high upfront pricing for one‑time gene‑editing therapies could restrict market access and dampen commercial uptake.
Safety RiskA patient meeting Hy's Law criteria who subsequently died prompted an analyst downgrade and underscores a serious safety concern that could limit nex-z adoption.
Intellia Therapeutics News
38I FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was €5.30 and its highest was €24.34 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is €1.34B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 54 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Feb 26, 2026. The company reported -€0.714 earnings per share for the quarter, beating the consensus estimate of -€0.822 by €0.108.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -0.79.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 118,133,545 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -€0.714 in its last earnings report, beating expectations of -€0.822. Following the earnings report the stock price went up 4.803%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in DE:38I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€18.12 (57.83% Upside)
€18.12 (57.83% Upside)
Blogger Sentiment
Bullish
DE:38I Sentiment 85%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $897.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.41%
12-Months-Change
Fundamentals
Return on Equity
-53.48%
Trailing 12-Months
Asset Growth
-29.29%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
38I Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of important clinical and commercial progress — most notably the completed Phase 3 enrollment and upcoming pivotal readout for lonvo-z, strong patient and physician interest, durable early efficacy signals, and improved near-term financial metrics — alongside meaningful risks: a still-pending FDA hold on the large cardiomyopathy ATTR program driven by serious liver enzyme events (including one patient death), material year-over-year cash depletion, and incomplete understanding of the safety signal’s mechanism and breadth. Management has secured a partial regulatory win (MAGNITUDE-2 hold lifted with specific mitigations) and emphasizes preparedness for a potential lonvo-z launch, but the unresolved MAGNITUDE hold and safety uncertainty inject non-trivial downside risk.View all DE:38I earnings summaries38I Revenue Breakdown
100.00% Collaboration revenue
38I Stock 12 Month Forecast
Average Price Target
€18.12
▲(57.83% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―
Options Prices
Currently, No data available
---